An Adult Mouse Model of Vibrio cholerae-induced Diarrhea for Studying Pathogenesis and Potential Therapy of Cholera

PLoS Neglected Tropical Diseases

Volumn 7, Issue 6, 2013, Pages

  Sawasvirojwong, Sutthipong ^a   Srimanote, Potjanee ^b   Chatsudthipong, Varanuj ^a   Muanprasat, Chatchai ^a  

^a Mahidol University   (Thailand)

^b THAMMASAT UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLERA TOXIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FLUORESCEIN ISOTHIOCYANATE DEXTRAN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; CHOLERA; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM ELECTROPHYSIOLOGY; EDEMA; ELECTRIC RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; INTESTINE FLUID; INTESTINE MUCOSA PERMEABILITY; MOUSE; MUCUS SECRETION; NONHUMAN; PATHOPHYSIOLOGY; REPRODUCIBILITY; SURVIVAL RATE; VASCULAR DISEASE; VIBRIO CHOLERAE;

EID: 84879542158     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002293     Document Type: Article

References (31)

1. Zuckerman JN, Rombo L, Fisch A, (2007) The true burden and risk of cholera: implications for prevention and control. Lancet Infect Dis 7: 521-530.
2. Lipp EK, Huq A, Colwell RR, (2002) Effects of global climate on infectious disease: the cholera model. Clin Microbiol Rev 15: 757-770.
3. Weil AA, Ivers LC, Harris JB, (2012) Cholera: lessons from haiti and beyond. Curr Infect Dis Rep 14: 1-8.
4. Thiagarajah JR, Verkman AS, (2005) New drug targets for cholera therapy. Trends Pharmacol Sci 26: 172-175.
5. Donowitz M, Alpers DH, Binder HJ, Brewer T, Carrington J, et al. (2012) Translational approaches for pharmacotherapy development for acute diarrhea. Gastroenterology 142: e1-9.
6. Muanprasat C, Chatsudthipong V, (2013) Cholera: pathophysiology and emerging therapeutic targets. Future Med Chem 5: 781-798.
7. Hodges K, Gill R, (2010) Infectious diarrhea: Cellular and molecular mechanisms. Gut Microbes 1: 4-21.
8. Lencer WI, (2001) Microbes and microbial Toxins: paradigms for microbial-mucosal toxins. V. Cholera: invasion of the intestinal epithelial barrier by a stably folded protein toxin. Am J Physiol Gastrointest Liver Physiol 280: G781-786.
9. Kunzelmann K, Mall M, (2002) Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 82: 245-289.
10. Hoque KM, Woodward OM, van Rossum DB, Zachos NC, Chen L, et al. (2010) Epac1 mediates protein kinase A-independent mechanism of forskolin-activated intestinal chloride secretion. J Gen Physiol 135: 43-58.
11. de Hostos EL, Choy RK, Nguyen T, (2011) Developing novel antisecretory drugs to treat infectious diarrhea. Future Med Chem 3: 1317-1325.
12. Chatterjee D, Chaudhuri K, (2012) Vibrio cholerae O395 outer membrane vesicles modulate intestinal epithelial Cells in a NOD1 dependent manner and induces dendritic cell-mediated Th2/Th17 responses. J Biol Chem 288: 4299-4309.
13. Harrison LM, Rallabhandi P, Michalski J, Zhou X, Steyert SR, et al. (2008) Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation. Infect Immun 76: 5524-5534.
14. Ritchie JM, Waldor MK, (2009) Vibrio cholerae interactions with the gastrointestinal tract: lessons from animal studies. Curr Top Microbiol Immunol 337: 37-59.
15. Ritchie JM, Rui H, Bronson RT, Waldor MK, (2010) Back to the future: studying cholera pathogenesis using infant rabbits. MBio 1: e00047-10.
16. Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, et al. (1988) Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168: 1487-1492.
17. Klose KE, (2000) The suckling mouse model of cholera. Trends Microbiol 8: 189-191.
18. Basu S, Pickett MJ, (1969) Reaction of Vibrio cholerae and choleragenic toxin in ileal loop of laboratory animals. J Bacteriol 100: 1142-1143.
19. Muanprasat C, Sirianant L, Soodvilai S, Chokchaisiri R, Suksamrarn A, et al. (2012) Novel Action of the Chalcone Isoliquiritigenin as a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitor: Potential Therapy for Cholera and Polycystic Kidney Disease. J Pharmacol Sci 118: 82-91.
20. Luerang W, Khammee T, Kumpum W, Suksamrarn S, Chatsudthipong V, et al. (2012) Hydroxyxanthone as an inhibitor of cAMP-activated apical chloride channel in human intestinal epithelial cell. Life Sci 90: 988-994.
21. Chen C, Wang P, Su Q, Wang S, Wang F, (2012) Myosin light chain kinase mediates intestinal barrier disruption following burn injury. PLoS One 7: e34946.
22. Pinnell AE, Northam BE, (1978) New automated dye-binding method for serum albumin determination with bromcresol purple. Clin Chem 24: 80-86.
23. Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS, (2004) Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 126: 511-519.
24. Zhu J, Miller MB, Vance RE, Dziejman M, Bassler BL, et al. (2002) Quorum-sensing regulators control virulence gene expression in Vibrio cholerae. Proc Natl Acad Sci U S A 99: 3129-3134.
25. Chatterjee A, Dutta PK, Chowdhury R, (2007) Effect of fatty acids and cholesterol present in bile on expression of virulence factors and motility of Vibrio cholerae. Infect Immun 75: 1946-1953.
26. Abuaita BH, Withey JH, (2009) Bicarbonate Induces Vibrio cholerae virulence gene expression by enhancing ToxT activity. Infect Immun 77: 4111-4120.
27. Nielsen AT, Dolganov NA, Rasmussen T, Otto G, Miller MC, et al. (2010) A bistable switch and anatomical site control Vibrio cholerae virulence gene expression in the intestine. PLoS Pathog 6: e1001102.
28. Sack RB, Carpenter CC, (1969) Experimental canine cholera. I. Development of the model. J Infect Dis 119: 138-149.
29. Thiagarajah JR, Verkman AS, (2012) CFTR inhibitors for treating diarrheal disease. Clin Pharmacol Ther 92: 287-290.
30. Alam NH, Ashraf H, Khan WA, Karim MM, Fuchs GJ, (2003) Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. Gut 52: 1419-1423.
31. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, et al. (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110: 1651-1658.